Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 123Carcinoma, Hepatocellular 72Neoplasms 48Breast Neoplasms 48Small Cell Lung Carcinoma 46Lung Neoplasms 42Triple Negative Breast Neoplasms 40Colorectal Neoplasms 39Melanoma 35Urinary Bladder Neoplasms 33Neoplasm Metastasis 31Carcinoma, Transitional Cell 31Carcinoma, Renal Cell 29Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Prostatic Neoplasms 13Liver Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Endometrial Neoplasms 9Mesothelioma, Malignant 8Kidney Neoplasms 8

Interventions

Cisplatin 56Radiotherapy 34Radiotherapy, Intensity-Modulated 28Magnetic Resonance Spectroscopy 24Radiation 20Carboplatin 19pembrolizumab 17Specimen Handling 16Platinum 141,2-diaminocyclohexaneplatinum II citrate 14Paclitaxel 13Cetuximab 13Fluorouracil 10Surgical Procedures, Operative 9Docetaxel 9Biopsy 9Taxes 8Chemoradiotherapy 8Nivolumab 7Fluorodeoxyglucose F18 7Drug Therapy 7durvalumab 6Surveys and Questionnaires 6fludarabine 5X-Rays 5Observation 5Cyclophosphamide 5aldesleukin 4Standard of Care 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Oropharyngeal Neoplasms × atezolizumab × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06254911 2026-01-27

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Emory University

Phase 2 Suspended
20 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡